{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:55:21Z","timestamp":1790286921414,"version":"4.1.0"},"reference-count":78,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.jaad.2021.10.030","type":"journal-article","created":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T22:13:29Z","timestamp":1635459209000},"page":"605-613","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["BRAF inhibition and the spectrum of granulomatous reactions"],"prefix":"10.1016","volume":"87","author":[{"given":"James P.","family":"Pham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phoebe","family":"Star","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Phan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanni","family":"Loh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony M.","family":"Joshua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.jaad.2021.10.030_bib1","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1038\/ng.3361","article-title":"Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas","volume":"47","author":"Krauthammer","year":"2015","journal-title":"Nat Genet"},{"issue":"10","key":"10.1016\/j.jaad.2021.10.030_bib2","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1200\/JCO.2010.32.4327","article-title":"Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma","volume":"29","author":"Long","year":"2011","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.jaad.2021.10.030_bib3","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.jaad.2021.10.030_bib4","doi-asserted-by":"crossref","first-page":"LBA8500","DOI":"10.1200\/jco.2012.30.18_suppl.lba8500","article-title":"Phase III, randomized, open-label, multicenter trial (BREAK-3) comparing the BRAF kinase inhibitor dabrafenib (GSK2118436) with dacarbazine (DTIC) in patients with BRAFV600E-mutated melanoma","volume":"30","author":"Hauschild","year":"2012","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.jaad.2021.10.030_bib5","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S1470-2045(18)30142-6","article-title":"Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial","volume":"19","author":"Dummer","year":"2018","journal-title":"Lancet Oncol"},{"issue":"20","key":"10.1016\/j.jaad.2021.10.030_bib6","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","article-title":"Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma","volume":"371","author":"Long","year":"2014","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.jaad.2021.10.030_bib7","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.trecan.2020.05.009","article-title":"Clinical development of BRAF plus MEK inhibitor combinations","volume":"6","author":"Subbiah","year":"2020","journal-title":"Trends Cancer"},{"issue":"2","key":"10.1016\/j.jaad.2021.10.030_bib8","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.pharmthera.2013.11.011","article-title":"BRAF inhibitors in cancer therapy","volume":"142","author":"Johansson","year":"2014","journal-title":"Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.jaad.2021.10.030_bib9","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1093\/annonc\/mdt015","article-title":"Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients","volume":"24","author":"Boussemart","year":"2013","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.jaad.2021.10.030_bib10","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1001\/jamadermatol.2015.1745","article-title":"Cutaneous toxic effects of BRAF inhibitors alone and in combination with MEK inhibitors for metastatic melanoma","volume":"151","author":"Carlos","year":"2015","journal-title":"JAMA Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2021.10.030_bib11","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/CMR.0000000000000649","article-title":"Induced sarcoid-like reactions in patients with metastatic melanoma treated with dabrafenib and trametinib: a monocentric retrospective study","volume":"30","author":"Huynh","year":"2020","journal-title":"Melanoma Res"},{"issue":"10","key":"10.1016\/j.jaad.2021.10.030_bib12","doi-asserted-by":"crossref","first-page":"e348","DOI":"10.1111\/jdv.15636","article-title":"Sarcoidosis occurring during BRAF\/MEK inhibitors is associated with paradoxical ERK activation in Erdheim-Chester patients","volume":"33","author":"Amoura","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"10.1016\/j.jaad.2021.10.030_bib13","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1159\/000439400","article-title":"Sarcoidosis in patients treated with vemurafenib for metastatic melanoma: a paradoxical autoimmune activation","volume":"231","author":"Lheure","year":"2015","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2021.10.030_bib14","first-page":"gfaa372","article-title":"Clinical features of acute kidney injury in patients receiving dabrafenib and trametinib","author":"Seethapathy","year":"2020","journal-title":"Nephrol Dial Transpl"},{"issue":"4","key":"10.1016\/j.jaad.2021.10.030_bib15","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1111\/bjd.13958","article-title":"Cutaneous toxicities associated with vemurafenib therapy in 107 patients with BRAF V600E mutation-positive metastatic melanoma, including recognition and management of rare presentations","volume":"173","author":"Sinha","year":"2015","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2021.10.030_bib16","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.jaad.2018.07.051","article-title":"Immune checkpoint inhibitors and the development of granulomatous reactions","volume":"81","author":"Cornejo","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2021.10.030_bib17","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/CMR.0000000000000437","article-title":"Sarcoid-like reactions in patients receiving modern melanoma treatment","volume":"28","author":"Dimitriou","year":"2018","journal-title":"Melanoma Res"},{"issue":"8","key":"10.1016\/j.jaad.2021.10.030_bib18","doi-asserted-by":"crossref","first-page":"102587","DOI":"10.1016\/j.autrev.2020.102587","article-title":"Sarcoidosis related to checkpoint and BRAF\/MEK inhibitors in melanoma","volume":"19","author":"Rubio-Rivas","year":"2020","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.jaad.2021.10.030_bib19","doi-asserted-by":"crossref","first-page":"e14618","DOI":"10.1111\/dth.14618","article-title":"Challenges in sarcoidosis and sarcoid-like reactions associated to immune checkpoint inhibitors: a narrative review apropos of a case","volume":"34","author":"Apalla","year":"2021","journal-title":"Dermatol Ther"},{"issue":"6","key":"10.1016\/j.jaad.2021.10.030_bib20","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/1346-8138.13255","article-title":"Cutaneous granulomatous panniculitis and sarcoidal granulomatous papular eruption in a patient with metastatic melanoma treated with a BRAF inhibitor","volume":"43","author":"Leal","year":"2016","journal-title":"J Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2021.10.030_bib21","article-title":"Persistent granulomatous cutaneous drug eruption to a BRAF inhibitor","volume":"76","author":"Wali","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"10.1016\/j.jaad.2021.10.030_bib22","doi-asserted-by":"crossref","first-page":"e732","DOI":"10.1111\/jdv.16550","article-title":"Dermal fillers may induce late-onset adverse skin reactions in patients under BRAF inhibitors","volume":"34","author":"Ortiz-Brugu\u00e9s","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.jaad.2021.10.030_bib23","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1001\/jamadermatol.2013.7919","article-title":"Cutaneous granulomatous eruption and successful response to potent topical steroids in patients undergoing targeted BRAF inhibitor treatment for metastatic melanoma","volume":"150","author":"Park","year":"2014","journal-title":"JAMA Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2021.10.030_bib24","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/bjd.12279","article-title":"Novel cutaneous effects of combination chemotherapy with BRAF and MEK inhibitors: a report of two cases","volume":"169","author":"Green","year":"2013","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2021.10.030_bib25","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1159\/000499959","article-title":"Granulomatous reactions from tattoos following BRAF inhibitor therapy","volume":"11","author":"Giet","year":"2019","journal-title":"Case Rep Dermatol"},{"issue":"S1","key":"10.1016\/j.jaad.2021.10.030_bib26","first-page":"79","article-title":"A tattoo pigment reaction in a patient with metastatic melanoma treated with dabrafenib and trametinib","volume":"58","author":"Scott","year":"2017","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.jaad.2021.10.030_bib27","unstructured":"Ciciarelli V, Rossi M, Cortellini A, Rocco T, Russo G, Fargnoli M. Granulomatous tattoo reaction during treatment with dabrafenib and trametinib for metastatic melanoma. Paper presented at: 24th World Congress of Dermatology; June 10-15, 2019; Milan, Italy."},{"issue":"6","key":"10.1016\/j.jaad.2021.10.030_bib28","doi-asserted-by":"crossref","first-page":"e402","DOI":"10.1111\/pde.13613","article-title":"Granulomatous dermatitis secondary to vemurafenib in a child with Langerhans cell histiocytosis","volume":"35","author":"Chen","year":"2018","journal-title":"Pediatr Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2021.10.030_bib29","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/DAD.0000000000001276","article-title":"BRAF inhibitoraassociated granulomatous dermatitis: a report of 3 cases","volume":"41","author":"Ong","year":"2019","journal-title":"Am J Dermatopathol"},{"issue":"8","key":"10.1016\/j.jaad.2021.10.030_bib30","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/cup.13267","article-title":"Granulomatous dermatitis associated with ipilimumab therapy (ipilimumab associated granulomatous dermatitis)","volume":"45","author":"Kubicki","year":"2018","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.jaad.2021.10.030_bib31","article-title":"Cobimetinib- and vemurafenib-induced granulomatous dermatitis and erythema induratum: a case report","volume":"7","author":"Iafolla","year":"2019","journal-title":"SAGE Open Med Case Rep"},{"issue":"7","key":"10.1016\/j.jaad.2021.10.030_bib32","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.jdcr.2018.05.011","article-title":"Subclinical granulomas in benign skin lesions heralding the onset of BRAF and MEK inhibitor-associated granulomatous dermatitis in a patient with metastatic melanoma","volume":"4","author":"Korman","year":"2018","journal-title":"JAAD Case Rep"},{"issue":"10","key":"10.1016\/j.jaad.2021.10.030_bib33","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1097\/DAD.0000000000000281","article-title":"BRAF inhibitor-induced antitumoral granulomatous dermatitis eruption in advanced melanoma","volume":"37","author":"Garrido","year":"2015","journal-title":"Am J Dermatopathol"},{"issue":"10","key":"10.1016\/j.jaad.2021.10.030_bib34","first-page":"1050","article-title":"Granuloma annulare secondary to vemurafenib therapy for lung adenocarcinoma","volume":"16","author":"Jenkinson","year":"2017","journal-title":"J Drugs Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2021.10.030_bib35","first-page":"305","article-title":"Vemurafenib-induced granuloma annulare","volume":"14","author":"Lee","year":"2016","journal-title":"J Dtsch Dermatol Ges"},{"issue":"4","key":"10.1016\/j.jaad.2021.10.030_bib36","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/ajd.12226","article-title":"Dabrafenib-associated necrobiotic granulomatous reaction","volume":"55","author":"Carlos","year":"2014","journal-title":"Australas J Dermatol"},{"issue":"8","key":"10.1016\/j.jaad.2021.10.030_bib37","doi-asserted-by":"crossref","first-page":"e96","DOI":"10.1097\/DAD.0000000000000230","article-title":"Panniculitis with necrotizing granulomata in a patient on BRAF inhibitor (dabrafenib) therapy for metastatic melanoma","volume":"37","author":"Ramani","year":"2015","journal-title":"Am J Dermatopathol"},{"issue":"3","key":"10.1016\/j.jaad.2021.10.030_bib38","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1001\/archdermatol.2011.2842","article-title":"Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management","volume":"148","author":"Zimmer","year":"2012","journal-title":"Arch Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2021.10.030_bib39","doi-asserted-by":"crossref","first-page":"e8010","DOI":"10.5867\/medwave.2020.07.8010","article-title":"Panniculitis in association with target therapy in melanoma patient, what the dermatologist should know: a case report","volume":"20","author":"Manubens-Vargas","year":"2020","journal-title":"Medwave"},{"issue":"4","key":"10.1016\/j.jaad.2021.10.030_bib40","first-page":"283","article-title":"Xanthogranulomatous reaction to trametinib for metastatic malignant melanoma","volume":"102","author":"Min","year":"2018","journal-title":"Cutis"},{"issue":"1","key":"10.1016\/j.jaad.2021.10.030_bib41","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/bjd.12268","article-title":"Sarcoidosis associated with vemurafenib","volume":"169","author":"Adam","year":"2013","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2021.10.030_bib42","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1684\/ejd.2019.3640","article-title":"Atypical systemic sarcoid-like granulomatosis in two patients treated with BRAF and MEK inhibitors","volume":"29","author":"Assan","year":"2019","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jaad.2021.10.030_bib43","doi-asserted-by":"crossref","first-page":"579523","DOI":"10.3389\/fimmu.2020.579523","article-title":"Case report: immune-related toxicity during adjuvant treatment with BRAF plus MEK inhibitors in a melanoma patient","volume":"11","author":"Boutros","year":"2020","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.jaad.2021.10.030_bib44","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/CMR.0000000000000186","article-title":"Granulomatous nephritis and dermatitis in a patient with BRAF V600E mutant metastatic melanoma treated with dabrafenib and trametinib","volume":"25","author":"Jansen","year":"2015","journal-title":"Melanoma Res"},{"key":"10.1016\/j.jaad.2021.10.030_bib45","article-title":"Acute granulomatous interstitial nephritis in a patient with metastatic melanoma on targeted molecular therapy with dabrafenib and trametinib: a case report","author":"Krelle","year":"2021","journal-title":"Cancer Rep (Hoboken)"},{"issue":"25","key":"10.1016\/j.jaad.2021.10.030_bib46","doi-asserted-by":"crossref","first-page":"e7196","DOI":"10.1097\/MD.0000000000007196","article-title":"Glomerulonephritis and granulomatous vasculitis in kidney as a complication of the use of BRAF and MEK inhibitors in the treatment of metastatic melanoma: a case report","volume":"96","author":"Maanaoui","year":"2017","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10.1016\/j.jaad.2021.10.030_bib47","doi-asserted-by":"crossref","first-page":"50","DOI":"10.4274\/tjo.galenos.2019.79026","article-title":"Sarcoid-like granulomatous intraocular inflammation caused by vemurafenib treatment for metastatic melanoma","volume":"50","author":"\u00d6zt\u00fcrk","year":"2020","journal-title":"Turk J Ophthalmol"},{"key":"10.1016\/j.jaad.2021.10.030_bib48","article-title":"A case of Vogt-Koyanagi-Harada-like uveitis secondary to dabrafenib\/trametinib therapy for advanced melanoma","author":"Brambati","year":"2020","journal-title":"Eur J Ophthalmol"},{"issue":"9","key":"10.1016\/j.jaad.2021.10.030_bib49","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.oftal.2018.01.008","article-title":"Uveitis and serous retinal detachment secondary to systemic dabrafenib and trametinib","volume":"93","author":"Rueda-Rueda","year":"2018","journal-title":"Arch Soc Esp Oftalmol (Engl Ed)"},{"issue":"6","key":"10.1016\/j.jaad.2021.10.030_bib50","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1097\/CMR.0000000000000505","article-title":"Incomplete Vogt\u2013Koyanagi\u2013Harada disease following treatment with encorafenib and binimetinib for metastatic melanoma","volume":"28","author":"Diamantopoulos","year":"2018","journal-title":"Melanoma Res"},{"issue":"2","key":"10.1016\/j.jaad.2021.10.030_bib51","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1002\/hep.28692","article-title":"Vemurafenib-induced granulomatous hepatitis","volume":"65","author":"Spengler","year":"2017","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.jaad.2021.10.030_bib52","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1111\/jdv.14467","article-title":"Acute heart failure as a result of granulomatous myocarditis: case report on a patient with metastatic melanoma treated with dabrafenib and trametinib","volume":"32","author":"Winkler","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2021.10.030_bib53","author":"Howick"},{"issue":"11","key":"10.1016\/j.jaad.2021.10.030_bib54","doi-asserted-by":"crossref","first-page":"499","DOI":"10.5694\/mja17.00610","article-title":"Sarcoidosis: a state of the art review from the Thoracic Society of Australia and New Zealand","volume":"208","author":"Ahmadzai","year":"2018","journal-title":"Med J Aust"},{"issue":"5","key":"10.1016\/j.jaad.2021.10.030_bib55","doi-asserted-by":"crossref","first-page":"699.e1","DOI":"10.1016\/j.jaad.2011.11.965","article-title":"Sarcoidosis: a comprehensive review and update for the dermatologist: part I. Cutaneous disease","volume":"66","author":"Haimovic","year":"2012","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2021.10.030_bib56","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1136\/thx.2010.140319","article-title":"Sarcoidosis is a Th1\/Th17 multisystem disorder","volume":"66","author":"Facco","year":"2011","journal-title":"Thorax"},{"issue":"3","key":"10.1016\/j.jaad.2021.10.030_bib57","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.chest.2018.03.056","article-title":"Drug-induced sarcoidosis-like reactions","volume":"154","author":"Chopra","year":"2018","journal-title":"Chest"},{"issue":"13","key":"10.1016\/j.jaad.2021.10.030_bib58","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s10354-014-0269-x","article-title":"Sarcoidosis vs. sarcoid-like reactions: the two sides of the same coin?","volume":"164","author":"Tchernev","year":"2014","journal-title":"Wien Med Wochenschr"},{"issue":"11","key":"10.1016\/j.jaad.2021.10.030_bib59","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1177\/2040622318790197","article-title":"Epidemiology of sarcoidosis: current findings and future directions","volume":"9","author":"Arkema","year":"2018","journal-title":"Ther Adv Chronic Dis"},{"issue":"1","key":"10.1016\/j.jaad.2021.10.030_bib60","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1159\/000213245","article-title":"Sarcoidosis and melanoma: a referral center study of 1,199 cases","volume":"219","author":"Seve","year":"2009","journal-title":"Dermatology"},{"issue":"11","key":"10.1016\/j.jaad.2021.10.030_bib61","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1182\/blood-2017-03-771873","article-title":"Targeted therapies in 54 patients with Erdheim-Chester disease, including follow-up after interruption (the LOVE study)","volume":"130","author":"Cohen Aubart","year":"2017","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jaad.2021.10.030_bib62","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/joim.12991","article-title":"Drug-induced sarcoidosis: an overview of the WHO pharmacovigilance database","volume":"288","author":"Cohen Aubart","year":"2020","journal-title":"J Intern Med"},{"issue":"5","key":"10.1016\/j.jaad.2021.10.030_bib63","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/j.1525-1470.2007.00508.x","article-title":"Interstitial granulomatous lesions as part of the spectrum of presenting cutaneous signs in pediatric sarcoidosis","volume":"24","author":"Kwon","year":"2007","journal-title":"Pediatr Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2021.10.030_bib64","first-page":"365","article-title":"Palisaded neutrophilic and granulomatous dermatitis in association with sarcoidosis","volume":"38","author":"Mahmoodi","year":"2011","journal-title":"J Cutan Pathol"},{"issue":"4","key":"10.1016\/j.jaad.2021.10.030_bib65","first-page":"245","article-title":"Palisaded neutrophilic and granulomatous dermatitis in association with subcutaneous nodular and systemic sarcoidosis","volume":"21","author":"Pa\u0161tar","year":"2013","journal-title":"Acta Dermatovenerol Croat"},{"issue":"9","key":"10.1016\/j.jaad.2021.10.030_bib66","doi-asserted-by":"crossref","first-page":"e371","DOI":"10.1016\/S1470-2045(14)70072-5","article-title":"Systemic treatment for BRAF-mutant melanoma: where do we go next?","volume":"15","author":"Menzies","year":"2014","journal-title":"Lancet Oncol"},{"issue":"15","key":"10.1016\/j.jaad.2021.10.030_bib67","doi-asserted-by":"crossref","first-page":"4499","DOI":"10.1158\/1078-0432.CCR-05-2447","article-title":"Cutaneous melanoma subtypes show different BRAF and NRAS mutation frequencies","volume":"12","author":"Saldanha","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.jaad.2021.10.030_bib68","doi-asserted-by":"crossref","first-page":"1372036","DOI":"10.1080\/2331205X.2017.1372036","article-title":"Sarcoidosis is not associated with BRAFV600E mutation","volume":"4","author":"Becker","year":"2017","journal-title":"Cogent Med"},{"issue":"5","key":"10.1016\/j.jaad.2021.10.030_bib69","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.4049\/jimmunol.1302616","article-title":"Dynamics of chemokine, cytokine, and growth factor serum levels in BRAF-mutant melanoma patients during BRAF inhibitor treatment","volume":"192","author":"Wilmott","year":"2014","journal-title":"J Immunol"},{"issue":"12","key":"10.1016\/j.jaad.2021.10.030_bib70","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1111\/all.13972","article-title":"Vemurafenib acts as an aryl hydrocarbon receptor antagonist: implications for inflammatory cutaneous adverse events","volume":"74","author":"Hawerkamp","year":"2019","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.jaad.2021.10.030_bib71","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1755-1536-4-10","article-title":"Immune response CC chemokines CCL2 and CCL5 are associated with pulmonary sarcoidosis","volume":"4","author":"Palchevskiy","year":"2011","journal-title":"Fibrogenesis Tissue Repair"},{"issue":"2","key":"10.1016\/j.jaad.2021.10.030_bib72","doi-asserted-by":"crossref","first-page":"e988039","DOI":"10.4161\/2162402X.2014.988039","article-title":"BRAF-inhibition and tumor immune suppression","volume":"4","author":"Steinberg","year":"2015","journal-title":"Oncoimmunology"},{"issue":"7","key":"10.1016\/j.jaad.2021.10.030_bib73","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1007\/s12094-020-02546-w","article-title":"Sarcoidosis-like reactions in cancer patients treated with immune checkpoint inhibitors: experience in a Spanish hospital","volume":"23","author":"Torres-Jim\u00e9nez","year":"2021","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.jaad.2021.10.030_bib74","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ejca.2020.02.024","article-title":"Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy: increased rate and mimicker of metastasis","volume":"131","author":"Chorti","year":"2020","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.jaad.2021.10.030_bib75","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/CMR.0000000000000169","article-title":"Complete remission of metastatic melanoma upon BRAF inhibitor treatment\u2014what happens after discontinuation?","volume":"25","author":"Tolk","year":"2015","journal-title":"Melanoma Res"},{"issue":"3","key":"10.1016\/j.jaad.2021.10.030_bib76","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/CMR.0000000000000350","article-title":"BRAF inhibitor discontinuation and rechallenge in advanced melanoma patients with a complete initial treatment response","volume":"27","author":"Desvignes","year":"2017","journal-title":"Melanoma Res"},{"key":"10.1016\/j.jaad.2021.10.030_bib77","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ejca.2020.11.010","article-title":"Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: a landmark analysis in patients with advanced melanoma","volume":"144","author":"Robert","year":"2021","journal-title":"Eur J Cancer"},{"issue":"7","key":"10.1016\/j.jaad.2021.10.030_bib78","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.mayocp.2018.11.033","article-title":"TNF-alpha inhibition and other immunosuppressants in the development of uveal and cutaneous melanoma","volume":"94","author":"Damento","year":"2019","journal-title":"Mayo Clin Proc"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962221026888?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962221026888?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T23:05:08Z","timestamp":1759273508000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962221026888"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":78,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S0190962221026888"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2021.10.030","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"BRAF inhibition and the spectrum of granulomatous reactions","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2021.10.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}